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New Global Burden of Disease estimates for liver cirrhosis, published in BMC Medicine, suggest that cirrhosis caused
over a million deaths in 2010, with a further million due to liver cancer and acute hepatitis. Cause-specific mortality
data were very sparse for some regions, particularly in Africa, with no relevant mortality data for 58/187 countries.
Liver disease involves infectious, malignant and chronic aetiologies with overlapping symptoms. Where available
mortality data come from verbal autopsies, separating different types of liver disease is challenging.
Cirrhosis is a disease of rich and poor alike; key public health risk factors such as alcohol consumption play an
important role. Risk-reduction strategies such as controlling the price of alcohol are being widely discussed. Since
these estimates used alcohol consumption as a covariate, they cannot be used to explore relationships between
alcohol consumption and cirrhosis mortality.
There is hope: coming generations of adults will have been vaccinated against hepatitis B, and this is envisaged to
reduce the burden of fatal liver disease. But more complete civil registration globally is needed to fully understand
the burden of liver disease.
Please see related article: http://www.biomedcentral.com/1741-7015/12/145/abstract.
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Cirrhosis is late-stage liver disease, in which the liver de-
velops scarring as a result of various long-term challenges.
Precipitating causes of cirrhosis include viral hepatitis and
heavy alcohol consumption, and it is associated with risks
for developing primary hepatocellular carcinoma. Advanced
cirrhosis is a life-threatening condition with limited treat-
ment options.
In a new assessment of liver cirrhosis mortality from the
Global Burden of Disease (GBD) project, published in BMC
Medicine, a diversity of methods and data sources led to a
global estimate of just over one million deaths in 2010,
which was approximately 2% of all deaths [1]. AlongsideCorrespondence: peter.byass@epiph.umu.se
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unless otherwise stated.this, GBD estimates suggest a further million deaths were
due to liver cancer and acute hepatitis. Overall, therefore,
liver disease represents a considerable public health burden.
If every death from liver disease across the globe were
investigated and documented in an efficient, standardised
manner, we could proceed with much greater clarity into
the realm of public health strategies for reducing this global
burden. Unfortunately that is far from the case, and so the
sophisticated modelling techniques that GBD has brought
to bear on measuring cirrhosis and other liver disease are
important. Nevertheless, mathematical models of disease
patterns work best when fed with large quantities of high
quality data; great care has to be taken not to over-extend
modelling assumptions in trying to span the considerable
holes in whatever data may be available [2].
What do the estimates show?
As presented in the GBD study, the paucity of mortality
data on cirrhosis, particularly in sub-Saharan Africa, is
striking. For the overall 96,639 observations of cirrhosis
mortality for 1980-2010 used in the GBD model, Figure 1is is an Open Access article distributed under the terms of the Creative
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Figure 1 Ratio of observations used in the Global Burden of Disease model to the number of cirrhosis deaths estimated for 2010,
by country.
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http://www.biomedcentral.com/1741-7015/12/159shows the ratio of observations used to the number of
cirrhosis deaths estimated for 2010, by country. For 58/187
(31%) of countries there were no observations. Countries
where observations numbered less than 1% of estimated
deaths accounted for 39% of the world’s population. In
sub-Saharan Africa, excluding South Africa, over 90% of
observations came from verbal autopsy sources, mostly ori-
ginating from INDEPTH (International Network for the
Demographic Evaluation of Populations and their Health)
Network sites [3], rather than from national vital registra-
tion data. The GBD team appropriately notes that their es-
timates for sub-Saharan Africa must be treated cautiously.
Liver disease, of which cirrhosis is an important com-
ponent, encompasses infectious, malignant and chronic
disease processes arising from a wide range of aetiologies,
which also have some key symptomatology in common
(such as jaundice and abdominal distension). Accordingly
it becomes a cross-cutting concept in terms of cause of
death classifications [4]. This is turn brings methodological
challenges when diagnostic outcomes are unclear or incom-
plete. Verbal autopsy (where, for otherwise undocumented
deaths, a post-mortem interview is carried out with rela-
tives or witnesses of the death to ascertain circumstances
and symptoms, which can then be interpreted into a likely
cause of death) is the main source of cause of death data
where deaths are not routinely certified, as is the case for
much of Africa and Asia. For verbal autopsy procedures
in particular, assigning a cause of death with effective
discrimination between acute infectious hepatitis, liver
cancer or cirrhosis is likely to be challenging, unless the
interview respondent has a clear sense of a clinical
diagnosis. In the WHO 2012 verbal autopsy standard
[5], liver cirrhosis is included as cause of death categoryVA06.02, covering ICD-10 codes K70-K76, but it is
also likely in reality that some less well-defined cases
of cirrhosis may fall into VA06.01 (acute abdomen) or
VA98 (other and unspecified non-communicable disease).
In addition, there is a distinct possibility of misclassification
under VA02.02 (digestive neoplasms).
At the same time, it must be remembered that cirrhosis
is a disease of the rich as well as the poor. Every continent
on the GBD mortality map for 2010 includes countries with
cirrhosis mortality estimates both above 30 per 100,000 and
below 10 per 100,000. If all 187 countries are ranked by
estimated cirrhosis mortality rates for 2010, then the USA,
Germany and Portugal are all examples from the mid-
tertile, alongside others from Latin America, Africa and
Asia. This reflects the complex mixture of risk factors and
disease processes involved.
Alcohol consumption undoubtedly plays an important
role in the development of cirrhosis, cutting across geo-
graphic, political and economic boundaries. A national
study from Iceland has shown significant increases in cir-
rhosis mortality as state-controlled restrictions on alcohol
marketing have relaxed [6]. A modelling study of non-
communicable disease risk-reduction strategies has sug-
gested that reducing alcohol consumption (as one of six
risk factors) could contribute substantially to avoiding large
numbers of premature deaths worldwide [7]. Public health
strategies to achieve reductions in alcohol consumption at
the population level are also a matter of considerable de-
bate; it has been suggested that controlling the minimum
price of units of alcohol would specifically target heavy
drinkers, and thus those at greatest risk of cirrhosis [8].
However, the GBD estimates of cirrhosis mortality need
careful interpretation in relation to alcohol consumption as
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used as a covariate in the GBD modelling, and, particularly
for males, emerged as a highly ranked component of the
ensemble model. Therefore one must presume that alcohol
consumption strongly drove the mortality estimates, par-
ticularly for countries with limited mortality data, bringing
in an element of circularity between alcohol consumption
and cirrhosis mortality. Thus the GBD results should not
be used to explore relationships between alcohol consump-
tion (or other covariates) and cirrhosis mortality.
Signs of hope
From working in West Africa in the 1980s, one poignant
memory is of young adult males with severe liver disease
who were obviously present in almost every hospital
ward. Before AIDS-related mortality became common,
liver disease was well known as a major killer of young,
productive adults in that region. The majority of today’s
adults were born before hepatitis B vaccination was
widely implemented, but there are signs of hope that, in
decades to come, fatal adult liver disease as a consequence
of widespread hepatitis B infection in infancy will decrease
due to vaccination. The GBD estimates suggest that hepa-
titis B accounted for a particularly high population attrib-
utable fraction of cirrhosis mortality in sub-Saharan Africa
(though noting that estimates of chronic hepatitis B infec-
tion were included as a model covariate). At least it should
be possible to fill important gaps in the evidence base on
using hepatitis B vaccination for reducing fatal liver dis-
ease as the Gambia Hepatitis Intervention Study cohort
moves on into high-risk age groups [9].
Conclusion
The new GBD estimates of cirrhosis mortality are un-
doubtedly interesting and important. However, they
carry the major uncertainties associated with all such
modelling. They must therefore be regarded as an interim
solution, while the world, and Africa in particular, moves
towards much more effective and widespread civil regis-
tration systems to fill the data gaps [10].
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